| Name | Class | Ki / nM at CB1 | Ki / nM at CB2 | Selectivity | CLogP | Structure | Description |
|---|
| AM-087 | Dibenzopyran | 0.43 | | | 6.47 |  | Ananalgesic CB1 agonist derived from Δ8-THC substituted with a side chain on the 3-position, roughly 100 times as potent as THC. |
| AM-251 | Pyrazole derivative | 7.5 | | | 7.08 |  | Aninverse agonist at the CB1cannabinoid receptor that is structurally related to SR141716A (rimonabant), but has a higher binding affinity.[1] |
| AM-279 | | | | | | | A Schedule I substance in Alabama.[2] |
| AM-281 | | | | | | | N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide[1] |
| AM-356 | | 17.9 | 868 | | 5.55 |  | A synthetically created stable chiral analog ofanandamide, it acts on both cannabinoid receptors.[3] |
| AM-374 | | | | | | | Palmitylsulfonyl fluoride[4] |
| AM-381 | | | | | | | Stearylsulfonyl fluoride |
| AM-404 | | | | | 7.02 |  | An active metabolite of paracetamol (acetaminophen) and a likely inhibitor offatty acid amide hydrolase (FAAH) |
| AM-411 | | 6.80 | 52.0 | | |  | Anadamantyl-substituted derivative of Δ8-THC, it is a potent and fairly selective CB1full agonist and a moderately potent CB2 agonist. |
| AM-630 | | | 32.1 | CB2 (165×) | 4.19 |  | A potent and selective inverse agonist for the cannabinoid receptor CB2 and a weak partial agonist at CB1. |
| AM-661 | | | | | | | 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole[5] |
| AM-678 | | 9.00 ± 5.00 | 2.94 ± 2.65 | CB2 | 5.68 |  | Another name for JWH-018, it is a full agonist at both cannabinoid receptors with some selectivity for CB2. |
| AM-679 | | 13.5 | 49.5 | | 6.04 |  | An iodobenzoylindole which acts as a moderately potent agonist for both cannabinoid receptors. |
| AM-694 | | 0.08 | 1.44 | CB1 (18×) | 5.54 |  | An iodobenzoylindole which acts as a potent and selective agonist for the CB1 cannabinoid receptor.[6] |
| AM-735 | | 8.9 | 7.4 | | | | 3-bornyl-Δ8-THC, a mixed CB1 / CB2 agonist.[7] |
| AM-855 | | 22.3 | 58.6 | CB1 | 7.1 |  | An analgesic derivative of Δ8-tetrahydrocannabinol, it is an agonist at bothCB1 andCB2 with moderate selectivity for CB1. |
| AM-881 | | 5.3 | 95 | | | | A chlorine-substituted stereoisomer of anandamide.[3] |
| AM-883 | | 9.9 | 226 | | | | An allyl-substituted stereoisomer of anandamide.[3] |
| AM-905 | | 1.2 | 5.3 | CB1 | 4.98 |  | A potent and reasonably selective agonist for the CB1 cannabinoid receptor. |
| AM-906 | | 0.8 | 9.5 | CB1 | 4.98 |  | A potent and dodecally selective agonist for the CB1 cannabinoid receptor. |
| AM-919 | | 2.2 | 3.4 | CB1 | 6.21 |  | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. It is a derivative ofHU-210 and represents a hybrid structure between theclassical and nonclassical cannabinoid families. |
| AM-926 | | 2.2 | 4.3 | CB1 | | | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. |
| AM-938 | | 1.2 | 0.3 | CB2 (4×) | 5.92 |  | A potent agonist at both CB1 and CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. |
| AM-1116 | | 7.4 | | | | | A dimethylated stereoisomer of anandamide.[3] |
| AM-1172 | | | | | | | An endocannabinoid analog specifically designed to be a potent and selectiveinhibitor of AEA uptake that is resistant to FAAH hydrolysis. |
| AM-1220 | | 3.88 | 73.4 | CB1 (19×) | 4.73 |  | A potent and selective analgesic CB1 agonist (asracemate). The (R) enantiomer has around 1000× higher affinity for CB1 than (S) enantiomer.[8][9] |
| AM-1221 | | 52.3 | 0.28 | CB2 (187×) | |  | A potent and selective CB2 agonist. |
| AM-1235 | | 1.5 | 20.4 | CB1 (13×) | |  | A moderately CB1 selective agonist.[10] |
| AM-1241 | | | 3.4 | CB2 (80×) | |  | A potent and selective analgesic CB2 agonist.[11] |
| AM-1248 | | | | CB1 | |  | A moderately potent agonist with some selectivity for CB1, containing an unusual 3-(adamant-1-oyl) substitution on the indole ring. |
| AM-1710 | Cannabilactone | | | CB2 (54×) | |  | A CB2 selective cannabilactone.[12] Acts as a dual CB2 agonist / CB1 antagonist.[13] |
| AM-1714 | Cannabilactone | | | CB2 (490×) | 6.17 |  | A CB2 selective cannabilactone.[12] |
| AM-1902 | | | | | | | A nonclassical cannabinoid[14] |
| AM-2201 | | 1.0 | 2.6 | CB1 | 5.18 |  | A potent agonist at both CB1 and CB2 with moderate selectivity for CB1. |
| AM-2212 | | 1.4 | 18.9 | CB1 | | | A potent agonist at both CB1 and CB2 with dodecal selectivity for CB1.[5] |
| AM-2213 | | 3.0 | 30 | CB1 (10×) | | | A potent agonist at both CB1 and CB2.[5] |
| AM-2232 | | 0.28 | 1.48 | | 4.75 |  | A potent agonist at both CB1 and CB2.[10] |
| AM-2233 | | 1.8 | 2.2 | CB1 | 5.09 |  | The (R) enantiomer is potent and selective CB1 agonist used in131Iradiolabelled form to map distribution of CB1 receptors in brain.[15][16][17][18][19][20] |
| AM-2389 | | 0.16 | | CB1 (26×) | 6 |  | Classical cannabinoid derivative. |
| AM-3102 | | 33000 | 26000 | | | | An analog ofoleoylethanolamide, the endogenous agonist for proliferator-activated receptor α (PPARα). It also acts as a weak cannabinoid agonist. |
| AM-4030 | | 0.7 | 8.6 | CB1 (12×) | 6.17 |  | A potent agonist at both CB1 and CB2, it is dodecally selective for CB1. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. |
| AM-4054 | | 2.2 | | CB1 (40×) | | | A potent but slow-onset agonist.[21][22] |
| AM-4056 | | 0.041 | | | 6.51 |  | Another name for HU-243, it is a potent agonist at both the CB1 and CB2 receptors. |
| AM-4113 | | | | CB1 | | | A CB1 selective neutral antagonist.[23] |
| AM-6545 | | | | CB1 | 4.06 |  | A peripherally selectivesilent antagonist of CB1 receptors. |
| AM-7438 | | | | | |  | A potent agonist of CB1 and CB2 with reduced duration of action.[24] |
| AM-11245 | | | | | |  | |
